Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: This study tried to observe additional benefit of agomelatine (AGO) treatment for major depressive disorder (MDD) in routine practice. Methods: Retrospective chart review (n = 63) was conducted for additional benefit of combination with or switching to AGO in MDD patients without full remission. The primary endpoint was the mean change of Clinical Global Impression-Clinical Benefit (CGI-CB) total scores from baseline to the endpoint. Additional secondary endpoints were also collected. Results: The changes of CGI-CB (Z = −3.073, p = 0.002) and Montgomery-Åsberg Depression Rating Scale (Z = −3.483, p ＜ 0.001) total scores were significantly decreased from baseline to the endpoint, respectively. At the endpoint, the remission rate was 22.6% (n = 18) and 28.6% of patient had improvement in CGI-CB total scores at the endpoint. No significant adverse events were observed. Conclusion: This study has shown additional benefit of AGO treatment as combination or switching agent for MDD patients without full remission in routine practice. However, adequately-powered and well-controlled studies are necessary for generalization of the present findings.
Abstract
Objective: This study tried to observe additional benefit of agomelatine (AGO) treatment for major depressive disorder (MDD) in routine practice. Methods: Retrospective chart review (n = 63) was conducted for additional benefit of combination with or switching to AGO in MDD patients without full remission. The primary endpoint was the mean change of Clinical Global Impression-Clinical Benefit (CGI-CB) total scores from baseline to the endpoint. Additional secondary endpoints were also collected. Results: The changes of CGI-CB (Z = −3.073, p = 0.002) and Montgomery-Åsberg Depression Rating Scale (Z = −3.483, p ＜ 0.001) total scores were significantly decreased from baseline to the endpoint, respectively. At the endpoint, the remission rate was 22.6% (n = 18) and 28.6% of patient had improvement in CGI-CB total scores at the endpoint. No significant adverse events were observed. Conclusion: This study has shown additional benefit of AGO treatment as combination or switching agent for MDD patients without full remission in routine practice. However, adequately-powered and well-controlled studies are necessary for generalization of the present findings.
참고문헌 (20)
- Changsu Han, "The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study", Clinical Psychopharmacology and Neuroscience, 17(4), pp.495~502 (2019), 대한정신약물학회[DOI]
- Cheolmin Shin, "Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder", Clinical Psychopharmacology and Neuroscience, 19(2), pp.243~253 (2021), 대한정신약물학회[DOI]
- Jihoon Oh, "Effect of Home-based Self-administered Transcranial Direct Stimulation in Patients with Mild to Moderate Major Depressive Disorder: A Single-arm, Multicentral Trial", Clinical Psychopharmacology and Neuroscience, 21(2), pp.271~278 (2023), 대한정신약물학회[DOI]
- Cheolmin Shin, "Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial", Clinical Psychopharmacology and Neuroscience, 21(1), pp.135~146 (2023), 대한정신약물학회[DOI]
- Young Sup Woo, "The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines", Clinical Psychopharmacology and Neuroscience, 20(1), pp.37~50 (2022), 대한정신약물학회[DOI]
- Han C, "Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial-or non-responsive to current antidepressants : A multi-center, naturalistic study", J Psychiatr Res, 49, pp.75~82 (2014)
- Sheng Min Wang, "Agomelatine for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis", Clinical Psychopharmacology and Neuroscience, 18(3), pp.423~433 (2020), 대한정신약물학회[DOI]
- Kennedy SH, "Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder", J Affect Disord, 238, pp.122~128 (2018)
- Kennedy SH, "Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months", Eur Neuropsychopharmacol, 26, pp.378~389 (2016)
- Cipriani A, "Comparative efficacy and acceptability of 21antidepressant drugs for the acute treatment of adults with major depressive disorder : A systematic review and network meta-analysis", Lancet, 391, pp.1357~1366 (2018)
- Khoo AL, "Network meta-analysis and cost-effectiveness analysis of new generation antidepressants", CNS Drugs, 29, pp.695~712 (2015)
- Huang KL, "Comparison of agomelatine and selective serotonin reuptake inhibitors", serotonin-norepinephrine reuptake inhibitors in major depressive disorder : A meta-analysis of head-to-head randomized clinical trials, 2014, pp.48, 663~671
- Konstantakopoulos G, "The preclinical discovery and development of agomelatine for the treatment of depression", Expert Opin Drug Discov, 15, pp.1121~1132 (2020)
- Potměšil P, "What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?", Ther Adv Psychopharmacol, 9, pp.2045125319855206~ (2019)
- Fornaro M, "Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder : A 3 month follow-up case series", Ann Gen Psychiatry, 10, pp.5~ (2011)
- Mallinckrodt CH, "Differential antidepressant symptom efficacy : Placebo-controlled comparisons of duloxetine and SSRIs(fluoxetine, paroxetine, escitalopram)", Neuropsychobiology, 56, pp.73~85 (2007)
- Hieronymus F, "Influence of baseline severity on the effects of SSRIs in depression : An item-based, patient-level post-hoc analysis", Lancet Psychiatry, 6, pp.745~752 (2019)
- Leucht S, "Translating the HAM-D into the MADRS and vice versa with equipercentile linking", J Affect Disord, 226, pp.326~331 (2018)
- Hiranyatheb T, "The impact of residual symptoms on relapse and quality of life among Thai depressive patients", Neuropsychiatr Dis Treat, 12, pp.3175~3181 (2016)
- Rush AJ, "Combining medications to enhance depression outcomes(CO-MED) : Acute and long-term outcomes of a single-blind randomized study", Am J Psychiatry, 168, pp.689~701 (2011)